IOBT

IO Biotech (IOBT)

About IO Biotech (IOBT)

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

Details

Daily high

$1.13

Daily low

$1.03

Price at open

$1.05

52 Week High

$2.10

52 Week Low

$0.73

Market cap

71.2M

Dividend yield

0.00%

Volume

63,640

Avg. volume

798,049

P/E ratio

-.75

IO Biotech News